The "Oslo Patient": A Landmark Case of Sustained HIV Remission

A 63-year-old Norwegian man has maintained undetectable HIV levels for over five years after receiving a stem cell transplant from his brother—a rare and remarkable case of sustained remission.

Patient and Donor Background

The patient was diagnosed with HIV in 2006 and began antiretroviral therapy (ART) in 2010, achieving viral suppression. In 2018, he was diagnosed with myelodysplastic syndrome, a type of bone marrow cancer. After initial treatment and relapse, a hematopoietic stem cell transplant (HSCT) was pursued as a last-resort treatment.

The search for a donor initially focused on an unrelated individual with the CCR5Δ32/Δ32 genetic mutation, but none was found. Instead, the patient's 60-year-old brother was identified as a compatible donor. Crucially, the brother's CCR5Δ32/Δ32 mutation status—which removes the CCR5 receptor HIV typically uses to enter white blood cells—was discovered only on the day of the transplant procedure.

Transplant and Medical Findings

• Procedure: The patient received an allogeneic HSCT at Oslo University Hospital in 2018.
• Immune System Replacement: Two years post-transplant, analysis confirmed that donor-derived cells had completely replaced the patient's original immune cells in the blood, bone marrow, and gut tissue.
• HIV Testing: Researchers collected 65 million CD4 T cells (HIV's primary target) and found no replication-competent virus. Lymph tissue analysis in the gastrointestinal tract, a known reservoir for dormant HIV, also found no trace of the virus.
• ART Cessation: The patient stopped taking HIV medication 24 months after the transplant. No viral rebound has been detected as of five years post-transplant.
• Immune Response: Laboratory tests indicated the patient's new immune cells respond to common viruses but do not recognize HIV. Researchers observed a decline in HIV antibodies and noted that T cells stopped responding to HIV, suggesting the immune system's biological memory of the virus had faded.

"The absence of HIV-specific T cell responses in our data supports the hypothesis that such an absence correlates with sustained HIV remission." — The researchers, in their published paper

Complications and Proposed Mechanisms

Graft-Versus-Host Disease (GVHD) — The patient experienced a severe immune reaction after the transplant, which was treated with immune-modulating medication. He successfully overcame this complication.

Contribution to Remission: Researchers noted that the immune reaction from GVHD and the drugs used to manage it may have contributed to the elimination of HIV.

Researcher Statements and Analysis

Study co-author Dr. Marius Trøseid (Oslo University Hospital) stated the case represents a "likely cure," though the scientific community often conservatively uses the term "sustained remission." He added there is no formal consensus on when a patient can be declared cured of HIV.

Trøseid reported that the patient described feeling "like he has won the lottery twice" —citing remission from both cancer and HIV.

"The case of the Oslo patient contributes valuable evidence to the existing knowledge base regarding HIV cure cases." — The research team

Context and Limitations

Statistically Unlikely: Dr. Anders Eivind Myhre (Oslo University Hospital) noted that siblings have a 25% probability of being a transplant match, and the frequency of the double CCR5Δ32 mutation is approximately 1% in northern European populations—making this scenario statistically improbable.

Procedure Risks: HSCT is a high-risk procedure that reboots the immune system, leaving patients vulnerable to infection. Approximately 10–20% of individuals who undergo such transplants die within a year.

Scope of Treatment: Researchers emphasized that stem cell transplants are not a viable or practical option for a widespread HIV cure. The procedure is performed only as a last resort for life-threatening conditions like certain cancers.

Global Context: ART remains the standard treatment for HIV, effectively suppressing viral replication, preventing disease progression, and stopping transmission when taken consistently. Over 30 million people live with HIV worldwide, making this transplant approach unfeasible as a universal solution.

Previous Cases and Broader Research

This case adds to a small number of documented instances where HIV patients with blood cancers achieved long-term remission following stem cell transplants from donors with the CCR5Δ32 mutation. Prior cases involved unrelated donors. Recent cases have also been reported where remission occurred without the mutation or with only one copy of it.

Future Research Directions

• Benchmarking: The researchers suggest their testing methodology could serve as a benchmark for evaluating long-term remission in future transplant patients.
• Biomarker Identification: The research team proposes comparing existing HIV cure cases to identify effective biomarkers and conducting individual patient data meta-analyses with harmonized protocols.
• Functional Cure Development: Trøseid described such transplant cases as "stepping stones" toward a functional cure, which would control HIV without lifelong medication.
• Alternative Strategies: Researchers noted ongoing investigations into alternative approaches, including engineered antibodies, through initiatives such as the EU2Cure international consortium.